Anti-angiogenic therapy for high-grade glioma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-angiogenic therapy for high-grade glioma

Published:2018-11-22 Issue:11 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ameratunga Malaka¹,Pavlakis Nick²,Wheeler Helen²,Grant Robin³,Simes John⁴,Khasraw Mustafa⁵

Affiliation:

1. Alfred Hospital; Medical Oncology; Commercial Road Melbourne Victoria Australia 3004

2. Royal North Shore Hospital; Department of Medical Oncology; Pacific Highway St Leonards New South Wales Australia 2065

3. Western General Hospital; Edinburgh Centre for Neuro-Oncology (ECNO); Crewe Road Edinburgh Scotland UK EH4 2XU

4. The University of Sydney; NHMRC Clinical Trials Centre; Locked Bag 77 Camperdown NSW Australia 1450

5. NHMRC Clinical Trials Centre, The University of Sydney; Camperdown Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008218.pub4/epdf/full

Reference68 articles.

1. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma:the GENOM 009 randomized phase II trial;Balana;Journal of Neurooncology,2016

2. Phase III randomised trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma;Batchelor;Journal of Clinical Oncology,2013

3. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF;Chauffert;Annals of Oncology,2014

4. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma;Chinot;New England Journal of Medicine,2014

5. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio Trial;Sandmann;Journal of Clinical Oncology,2015

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitory effects of Gracilaria edulis and Gracilaria salicornia against the MGMT and VEGFA biomarkers involved in the onset and advancement of glioblastoma using in silico and in vitro approaches;Biotechnology and Applied Biochemistry;2024-08-21

2. Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis;Neurosurgical Review;2024-08-20

3. Targeting drug resistance in glioblastoma (Review);International Journal of Oncology;2024-07-09

4. Nanotechnology Driven Lipid and Metalloid Based Formulations Targeting Blood–Brain Barrier (3B) for Brain Tumor;Indian Journal of Microbiology;2024-06-21

5. Overcoming Resistance to Temozolomide in Glioblastoma: A Scoping Review of Preclinical and Clinical Data;Life;2024-05-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3